Exploring C4 Therapeutics, Inc. (CCCC) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in C4 Therapeutics, Inc. (CCCC) and what's driving their decisions? With 245 institutional owners and shareholders holding a total of 69,878,057 shares, the ownership structure reveals significant interest from major players. As of April 17, 2025, the share price stood at $1.25, a stark contrast to $6.72 on April 19, 2024, marking an 81.40% decline. Could this dip be a buying opportunity, or are there deeper concerns? Keep reading to find out which firms are leading the pack, what their investment strategies might be, and how recent developments, such as Wells Fargo's upgrade to 'Overweight' in December 2024 and an average one-year price target revision to $16.47, might influence future investment decisions.

C4 Therapeutics, Inc. (CCCC) Who Invests in [Company Name] and Why?

Understanding the investor profile of C4 Therapeutics, Inc. (CCCC) provides insights into market sentiment and the factors driving investment decisions. A variety of investors, from retail to institutional, are drawn to the company for different reasons.

Key investor types in C4 Therapeutics, Inc. (CCCC) include:

• Institutional Investors: These entities, such as mutual funds, hedge funds, and pension funds, make up a significant portion of C4 Therapeutics' shareholders. According to WallStreetZen, institutional investors own 90.72% of C4 Therapeutics.
• Retail Investors: Individual investors also hold a stake in C4 Therapeutics. According to TipRanks, retail investors hold approximately 66.33% of the company’s stock. However, WallStreetZen reports that retail investors own 0.00% of the company.
• Insiders: Company insiders, such as executives and board members, also hold shares. WallStreetZen indicates that insiders own 25.43% of C4 Therapeutics.

Major shareholders include:

• Soleus Capital Management, L.P.
• Lynx1 Capital Management LP
• Wasatch Advisors Inc
• BlackRock, Inc.
• Ra Capital Management, L.p.
• Orbimed Advisors Llc
• Morgan Stanley
• WAMCX - Wasatch Ultra Growth Fund Investor Class shares
• Vanguard Group Inc
• Samlyn Capital, Llc

These institutions hold a total of 69,878,057 shares.

Investment motivations for C4 Therapeutics, Inc. (CCCC) investors include:

• Growth Prospects: Investors are drawn to C4 Therapeutics' potential for growth in the biopharmaceutical industry, particularly in targeted protein degradation. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases.
• Market Position: C4 Therapeutics is dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines.

Typical investment strategies seen among C4 Therapeutics, Inc. (CCCC) investors are:

• Long-Term Holding: Some institutional investors adopt a long-term holding strategy, as evidenced by institutions and funds holding a total of 69,878,057 shares.
• Short-Term Trading: Given the dynamic nature of the biotechnology industry and C4 Therapeutics' ongoing clinical trials, some investors may engage in short-term trading to capitalize on price fluctuations.

C4 Therapeutics has secured substantial funding through various rounds:

• Series A: $73 million (Jan 07, 2016)
• Series B: $150 million (Jun 16, 2020)
• Venture Debt: $20 million (Jun 16, 2020)
• Post IPO: $25 million (Jan 04, 2024)

As of December 31, 2024, C4 Therapeutics had $267.3 million in cash, cash equivalents, and marketable securities, expected to provide runway into 2027.

For more information, you can also explore C4 Therapeutics, Inc. (CCCC): History, Ownership, Mission, How It Works & Makes Money.

C4 Therapeutics, Inc. (CCCC) Institutional Ownership and Major Shareholders of C4 Therapeutics, Inc. (CCCC)

Institutional ownership in C4 Therapeutics, Inc. (CCCC) plays a significant role in the company's stock performance and strategic direction. Examining the major shareholders and their recent activities provides valuable insights into market sentiment and potential future movements.

As of December 31, 2024, several institutional investors held substantial stakes in C4 Therapeutics, Inc. (CCCC). These major shareholders can exert considerable influence on the company's stock price and overall strategy.

Here's a list of some of the top institutional investors:

• RA Capital Management, L.P.: As of December 31, 2024, RA Capital Management, L.P. holds 3,999,467 shares of C4 Therapeutics, Inc. (CCCC), reflecting their confidence in the company's potential.
• RTW Investments, LP: RTW Investments, LP reported ownership of 2,575,493 shares as of December 31, 2024.
• FMR LLC: According to the latest filings, FMR LLC owns 2,448,523 shares in C4 Therapeutics, Inc. (CCCC) as of December 31, 2024.
• BlackRock Fund Advisors: BlackRock Fund Advisors holds 1,842,841 shares, demonstrating a significant stake in the company as of December 31, 2024.
• State Street Global Advisors, Inc.: State Street Global Advisors, Inc. owns 1,068,968 shares of C4 Therapeutics, Inc. (CCCC) as of December 31, 2024.

Changes in institutional ownership can signal shifts in investor confidence and expectations. Recent transactions by major shareholders often trigger market reactions, influencing the stock's volatility.

Based on recent data, some institutional investors have adjusted their positions in C4 Therapeutics, Inc. (CCCC):

• An increase in shares held by an institutional investor indicates a bullish outlook, suggesting they anticipate positive future performance.
• Conversely, a decrease in holdings may reflect concerns about the company's prospects or a strategic portfolio adjustment.

The actions of these large investors can have a pronounced effect on C4 Therapeutics, Inc. (CCCC)'s stock price and strategic decisions. Their investment decisions are often based on thorough research and analysis, making their activity a key indicator for other investors.

Institutional investors play a crucial role in shaping a company’s stock price through:

• Trading Activity: Large volume trades by these institutions can lead to significant price movements.
• Strategic Influence: Major shareholders often engage with company management, influencing strategic decisions and corporate governance.
• Market Confidence: Their investment decisions can enhance or diminish market confidence in the company.

Understanding the dynamics of institutional ownership provides valuable context for assessing C4 Therapeutics, Inc. (CCCC)'s market position and potential future trajectory.

For more insights into the company's values and objectives, explore the Mission Statement, Vision, & Core Values of C4 Therapeutics, Inc. (CCCC).

C4 Therapeutics, Inc. (CCCC) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of C4 Therapeutics, Inc. (CCCC) provides critical insights into the company's stability, growth potential, and strategic direction. Examining who is investing, their motivations, and their recent activities can significantly inform stakeholders about the perceived value and future prospects of CCCC.

While specific real-time data on all investors and their direct influence is dynamic and often confidential, we can analyze available information to understand the general landscape.

Institutional investors often hold significant stakes in companies like C4 Therapeutics, Inc. (CCCC). These may include:

• Vanguard Group: Known for its passive investment strategies and substantial holdings across various sectors.
• BlackRock: Another major asset manager with diverse investments.
• State Street Corporation: A key player in the investment management arena.
• Fidelity Investments: A large and well-known investment firm with a broad portfolio.

These firms typically invest based on extensive research and analysis, and their investment decisions can influence market perception and stock movement. Recent moves, such as increasing or decreasing their positions, are closely watched by other investors.

Hedge funds may also hold positions in C4 Therapeutics, Inc. (CCCC), seeking short-term gains through various trading strategies. Their activities can lead to increased volatility in the stock price.

While pinpointing individual influence is challenging, large institutional investors can impact company decisions through:

• Voting Rights: Significant shareholders have the power to influence the election of board members and vote on important company matters.
• Direct Engagement: Major investors often engage directly with company management to discuss strategy, performance, and governance.
• Market Signaling: Large trades by prominent investors can send signals to the market, influencing the behavior of other investors.

Keeping track of recent moves by major investors involves monitoring SEC filings (such as 13F filings, which disclose quarterly holdings) and news reports. These sources can reveal instances of large stake acquisitions or disposals, which may indicate investor sentiment and future expectations.

For instance, if a well-known fund announces a substantial new investment in C4 Therapeutics, Inc. (CCCC), it could boost confidence among other investors, leading to an increase in the stock price. Conversely, a significant sell-off by a major holder might trigger concern and downward pressure on the stock.

Here is a hypothetical example of institutional ownership in C4 Therapeutics, Inc. (CCCC). Please note that this is an example and not based on real-time data:

Understanding these dynamics is crucial for anyone looking to invest in or understand C4 Therapeutics, Inc. (CCCC). Monitoring investor activity and influence provides valuable context for assessing the company's potential and navigating the complexities of the stock market.

To gain more insights into the values and objectives that drive C4 Therapeutics, Inc. (CCCC), explore: Mission Statement, Vision, & Core Values of C4 Therapeutics, Inc. (CCCC).

C4 Therapeutics, Inc. (CCCC) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating C4 Therapeutics, Inc. (CCCC). Recent ownership changes and large investor moves can significantly influence the stock's performance. Analyst perspectives provide further insights into how these factors might affect the company's future.

Several institutional investors have adjusted their stakes in C4 Therapeutics, Inc. (CCCC). For instance:

• FMR LLC reduced its holdings by 21.7% in the fourth quarter of 2023.
• State Street Corp decreased its position by 2.2% during the same period.
• Conversely, Geode Capital Management LLC increased its stake by 3.5% in the fourth quarter of 2023.
• Vanguard Group Inc. raised its holdings by 2.4% during the same period.
• BlackRock Inc. increased its stake by 4.1% in the fourth quarter of 2023.

These changes reflect varied investor strategies and expectations regarding C4 Therapeutics, Inc. (CCCC).

Here is a snapshot of significant institutional ownership:

Institutional investors, in aggregate, own 74.77% of C4 Therapeutics, Inc. (CCCC). This substantial institutional ownership suggests that the company's stock performance is closely monitored by these large entities.

Recent market reactions to these ownership changes have been mixed. While some investors may view increased stakes as a positive signal, indicating confidence in the company's prospects, others might interpret reductions as a sign of concern. These reactions can influence short-term stock movements and overall market sentiment.

Analysts play a crucial role in interpreting these investor activities. Their perspectives often consider the underlying reasons for the changes in ownership, such as:

• Company performance
• Pipeline developments
• Broader market trends

These analyses can provide valuable context for understanding the potential impact on C4 Therapeutics, Inc. (CCCC)'s future.

For additional insights into C4 Therapeutics, Inc. (CCCC)'s mission, vision, and core values, refer to: Mission Statement, Vision, & Core Values of C4 Therapeutics, Inc. (CCCC).